Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.

European journal of pediatrics - 1 Jan 2022

Panigrahy Nalinikanta, Chirla Dinesh Kumar, Bagga Nitasha, Gunda Ranjit Kumar, Sukhija Bharat, Reddy Leenatha

Abstract excerpt

Congenital hyperinsulinism (CHI) is the most common cause of persistent hypoglycaemia in neonates and infants. Medical treatment includes the use of high concentrations of glucose and combinations of diazoxide, octreotide and glucagon. We report our experience of using sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, in the treatment of CHI in seven newborns who are poorly responding to standard...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Congenital Hyperinsulinism
Share to Diazoxide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucose

Share to Hyperinsulinism

Share to Infant

Share to Infant, Newborn

Share to Mutation

Share to Sirolimus

Source

Identifiers

PMID: 34304300
DOI: 10.1007/s00431-021-04209-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sirolimus in infants with congenital hyperinsulinism (CHI) - a single-centre experience.PMID 34304300Read ↗

Sirolimus therapy for congenital hyperinsulinism in an infant with a novel homozygous KCNJ11 mutation.Semantic proximity Read ↗

Sirolimus in the treatment of three infants with diffuse congenital hyperinsulinism.Semantic proximity Read ↗

mTOR Inhibitors for the Treatment of Severe Congenital Hyperinsulinism: Perspectives on Limited Therapeutic SuccessSemantic proximity Read ↗

Evaluation and management of neonatal onset hyperinsulinemic hypoglycemia: a single neonatal center experience.Semantic proximity Read ↗

Congenital Hyperinsulinism.Semantic proximity Read ↗

Molecular Characterization and Management of Congenital Hyperinsulinism: A Tertiary Centre Experience.Semantic proximity Read ↗

Sirolimus therapy in a patient with severe hyperinsulinaemic hypoglycaemia due to a compound heterozygous ABCC8 gene mutation.Semantic proximity Read ↗

Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia.Semantic proximity Read ↗

A Novel Homozygous Mutation in the KCNJ11 Gene of a Neonate with Congenital Hyperinsulinism and Successful Management with Sirolimus.Semantic proximity Read ↗

Congenital hyperinsulinism in infancy and childhood: challenges, unmet needs and the perspective of patients and familiesSemantic proximity Read ↗

Congenital hyperinsulinism: current trends in diagnosis and therapySemantic proximity Read ↗

Extreme caution on the use of sirolimus for the congenital hyperinsulinism in infancy patientSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.